Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting

Core Insights - Evoke Pharma, Inc. is set to present two posters at the American College of Gastroenterology Annual Scientific Meeting, highlighting the use of its product Gimoti® (metoclopramide) nasal spray in treating gastrointestinal diseases [1] - One of the posters, P3339, has received the ACG's Outstanding Research Award and the Presidential Poster Award, indicating its high impact and excellence in research [1] Company Overview - Evoke Pharma is a specialty pharmaceutical company focused on developing treatments for gastrointestinal disorders, particularly diabetic gastroparesis [2] - Gimoti is a nasal spray formulation of metoclopramide, specifically designed for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults [2] - Diabetic gastroparesis affects millions globally, causing delayed gastric emptying and serious gastrointestinal symptoms, with Gimoti being the only FDA-approved treatment for this condition in the U.S. [2]